Atacicept as an investigated therapy for rheumatoid arthritis.

Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke, Bernard Bannwarth

Expert opinion on investigational drugs 2014 Sep

filter terms:

Rheumatoid arthritis (RA) is a chronic, painful and debilitating autoimmune disease. Although the outcome for patients with RA has improved markedly in the past decades, adequate disease control cannot be achieved in a substantial proportion of patients. Since RA is a syndrome with different biological subsets, new drugs with a novel mechanism of action may represent a valuable addition to the current armamentarium. This review focuses on the pharmacodynamics and pharmacokinetics of atacicept . Furthermore, the article both summarises and comments on the drug's efficacy and safety profile in RA patients. Atacicept is designed to neutralise B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand, two cytokines involving B-cell function and survival. Two recent Phase II studies have demonstrated that atacicept was not effective in RA patients with an inadequate response to methotrexate or TNF antagonists. However, atacicept displayed significant biological activity, including reduction of Ig and rheumatoid factor levels. Adverse events were slightly more frequent among patients treated with atacicept compared with placebo. In contrast to patients with systemic lupus erythematosus, RA patients receiving atacicept did not show an increased susceptibility to infections. In view of its important impact on immunoglobulin-secreting cells, this drug might be a rational therapy for hematological diseases.

Citation

Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke, Bernard Bannwarth. Atacicept as an investigated therapy for rheumatoid arthritis. Expert opinion on investigational drugs. 2014 Sep;23(9):1285-94